Flutoxil

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flutoxil

Quick Facts

Property Description
Active ingredient Bromhexine hydrochloride
Form Oral liquid (Syrup, Solution), Tablet
Pharmacological class Mucolytic, Secretolytic Expectorant
Common purpose Management of secretion disorders
Origin Synthetic organic compound

What is Flutoxil and Its Pharmacological Classification?

Flutoxil is a medicinal product defined by its single, synthetic organic active ingredient, Bromhexine hydrochloride. It is primarily categorized as a mucolytic and a secretolytic expectorant, signifying its function is to act upon the physical characteristics of respiratory secretions to aid expulsion. This classification identifies it as a specialized agent for managing phlegm. The reduction of mucus viscosity is a characteristic action for this class of mucoactive agents.

Active Ingredient: Bromhexine and Drug Forms

  • The formulation of Flutoxil centers on Bromhexine hydrochloride, making it a single-ingredient therapeutic product designed for a targeted effect. The most frequently used formats for oral intake are the oral liquid forms, such as the syrup or solution, which are often formulated with specific flavorings to improve palatability for children and adults. The active ingredient is designed to facilitate the thinning and mobilization of viscous mucus. This provides a focused approach, differentiating it from combination products that include ingredients such as cough suppressants or decongestants.

General Purpose: Managing Secretion Disorders

  • The general purpose of Flutoxil is to address secretion disorders within the respiratory system that produce thick, tenacious mucus, such as those associated with the common cold or bronchitis. Bromhexine's mucoactive properties involve the hydrolytic depolymerization of complex mucopolysaccharide fibers in the phlegm, which consequently reduces its viscosity and elasticity. By transforming the secretions into a thinner, more manageable fluid, Flutoxil supports the development of a more effective, productive cough for expelling excessive mucus. This targeted action is intended for facilitating easier breathing and clearance.

Regulatory References

  1. Bromhexine hydrochloride

What side effects are possible with Flutoxil?

Possible Side Effects and Safety Information

The safety profile for Flutoxil (Bromhexine hydrochloride) is officially documented by regulatory authorities, with adverse reactions classified by frequency and affected physiological systems. The majority of reported effects fall under Gastrointestinal disorders.

Classification Examples of Documented Effects
Uncommon ( ge 1/1,000 to < 1/100 ) Nausea, Vomiting, Diarrhoea, Upper abdominal pain, Fever
Rare ( ge 1/10,000 to < 1/1,000 ) Hypersensitivity reactions, Rash, Urticaria, Headache, Dizziness

Serious adverse reactions, though classified as Not Known (frequency cannot be estimated from available data), include severe reactions such as anaphylactic shock and several types of Severe Cutaneous Adverse Reactions (SCARs), including Stevens-Johnson syndrome (SJS) and Toxic epidermal necrolysis (TEN). Regulatory documents note that these serious skin reactions are generally reported to occur early in treatment.

Specific safety considerations are mandated for certain patient populations. Caution is required in individuals with severe hepatic or renal impairment due to potential changes in drug clearance. Furthermore, caution is advised for patients with a history of gastric ulceration or those with impaired bronchial motor function that limits the effective clearance of secretions. The medicine is contraindicated in patients with known hypersensitivity to the active ingredient.

Overdose and Emergency Response

The official regulatory documentation for Flutoxil (Bromhexine hydrochloride) defines the overdose profile primarily by the absence of unique clinical manifestations and the presence of mandated immediate action.

Regulatory sources state that no specific overdose symptoms have been reported in humans following Bromhexine exposure. Instead, the clinical presentation is consistent with the known side effects of the medicine. These documented manifestations affect physiological systems, including the gastrointestinal system (such as nausea, vomiting, upper abdominal pain, and diarrhea) and the nervous system (including headache and dizziness).

When Immediate Medical Help is Required

In the event of a suspected or confirmed overdose, regulatory authorities mandate that urgent action must be taken. The required first step is to seek immediate medical attention by contacting the national Poisons Information Centre or an equivalent emergency service for expert advice.

Management of an overdose case is described strictly as supportive and symptomatic treatment. The official prescribing information notes that no specific antidote is known for Bromhexine overdose. Furthermore, regulatory documents do not list specific severe, life-threatening outcomes unique to Bromhexine overdose or any special monitoring requirements beyond general supportive care. No population-specific considerations regarding severity or management (e.g., for pediatric or hepatic patients) are explicitly documented in the official overdose sections.

Therapeutic Uses of Flutoxil

What Flutoxil Treats: Main Uses and Benefits

The primary therapeutic role of Flutoxil is generally used to offer supportive relief in respiratory conditions where the principal challenge is the presence of abnormal, thick, or excessive mucus, which is difficult for the patient to clear.


Symptomatic Relief and Airway Support

Flutoxil is indicated for the management of symptoms related to thick mucus and to help clear chest congestion. It is applied in conditions characterized by viscid or tenacious secretions, such as acute bronchitis, the common cold, and influenza. This medication helps address symptom clusters that create noticeable physiological strain by addressing symptoms related to viscous secretions in the respiratory tract.

“This supportive function contributes to easing the overall symptom load and supports general well-being during symptomatic phases.”

The use of this therapeutic support is typically associated with instances where the patient experiences difficulty in expectoration due to the quality of the phlegm, or when dealing with a strained or ineffective cough. It assists with the management of symptoms that interfere with routine activities by helping the patient expel accumulated secretions more easily, offering symptomatic relief that helps patients cope more steadily during difficult episodes. The medicine is commonly used in both adults and children requiring support for secretion disorders.


Quick Fact: Relief for Viscid Mucus

Property Description
Primary Therapeutic Goal Management of excessively thick secretions
Symptom Cluster Addressed Impaired expectoration and chest congestion
Common Clinical Context Acute respiratory infections (e.g., bronchitis)
Core Patient Benefit Supports easier airway clearance

Regulatory References

  1. Australian Therapeutic Goods Administration OTC Monograph

Eligibility and Restrictions for Use

Who can and cannot use Flutoxil? — Official Regulatory Information

Official regulatory documents define specific populations who must not use Flutoxil, primarily based on established contraindications. These restrictions are non-negotiable and grounded in the drug's official labeling.

Contraindicated Populations

Regulatory agencies state that Flutoxil is absolutely contraindicated (must not be used) in the following groups:

  • Hypersensitivity: Patients with a known allergy or severe reaction to the active substance Flutoxil or to any of the inactive components (excipients) in the formulation.
  • Pregnancy: Use of the medicine is formally contraindicated during pregnancy.

Other Restricted Use

Official labeling may also advise against use in certain physiological states, indicating a need for caution or restriction. The medicine is not recommended for use in women who are breastfeeding (lactation).

Age-Related Eligibility

Use of Flutoxil is generally restricted to the adult population and specific pediatric age groups for which the safety and effectiveness profile has been formally established and authorized in the regulatory documents. Use outside of these specified age ranges is not covered by the official label.

What should I know about interactions with other medicines?

The official regulatory profile for Flutoxil (Bromhexine hydrochloride) establishes a low potential for unfavorable drug-drug interactions. Regulatory agencies confirm that no clinically relevant unfavourable interactions have been reported with most co-administered medications, and there are no formal contraindications stemming from metabolic or transporter pathway restrictions. Interactions with CYP 450 2C9 or 3A4 substrates are considered unlikely according to available data.

A specific, documented interaction involves an effect on local drug distribution. Co-administration of Flutoxil with the antibiotics Amoxicillin, Erythromycin, or Oxytetracycline results in a pharmacokinetic/distribution effect that increases the concentrations of these antibiotics in the sputum and bronchopulmonary secretions.

A clear pharmacodynamic restriction is established: the medicine must not be associated with antitussives or secretion-drying medications. This restriction is due to the counteracting effect of these agents, which oppose the intended goal of secretion thinning. Furthermore, a drug-food interaction is documented, noting that concomitant food intake increases the plasma concentration of the active ingredient. No mandatory timing separation rules for administration are documented in the official labeling.

Mechanism of Action

How Flutoxil Works

Flutoxil exerts its pharmacodynamic activity across three core mechanistic domains to modulate the processes governing airway clearance.

Chemical Thinning of Secretions (Mucus Rheology Modulation)

This mechanism involves direct molecular interaction with acidic polysaccharide fibers (mucins) within the bronchial secretions. The active component acts to depolymerize or break down these macromolecules, which reduces the intrinsic viscosity and adhesiveness of the mucus. This molecular restructuring facilitates the conversion of high-viscosity secretions into a low-viscosity, more fluid state.

Modulation of Airway Clearance (Mucociliary Kinematics)

The drug influences the Mucociliary Clearance (MCC) system by stimulating the cilia of the respiratory epithelium. This stimulation increases the ciliary beat frequency, promoting the physical upward transport of material. This enhanced mechanical action facilitates the movement of thinned secretions out of the respiratory tract.

Influence on Lung Surface Integrity (Surfactant Modulation)

Flutoxil influences Type II pneumocytes to increase the synthesis and secretion of pulmonary surfactant. Surfactant stabilizes the structure of the small air sacs and airways and contributes to the surface-active properties of the pulmonary environment, further assisting the spreading of the mucus layer.

Dosage and Administration Information

General Administration Guidelines

Flutoxil, which contains Bromhexine hydrochloride, is designated for oral administration and is available in forms such as tablets and oral solutions or syrups.


Labeled Dosing Regimens and Frequency

Population Standard Dosing Regimen Maximum Daily Limit
Adults and Children > 12 years 8 mg per dose, three times daily May be increased to 16 mg per dose, three times daily for the first seven days
Children 6 – 11 years 8 mg per dose, three times daily Use in this age group is typically restricted to only on the advice of a healthcare professional

The medicine is generally taken three times daily (t.i.d.), administered as necessary for symptom management. The total daily maximum dose must not be exceeded.


Administration Context and Duration

To ensure correct administration, liquid formulations must be measured using the calibrated measuring cup or spoon provided in the package. Flutoxil may be taken with or without food; however, technical labeling indicates that concomitant food intake can lead to an increase in plasma concentrations.

Use is generally restricted to a short course. The medication should not be used for more than seven consecutive days without medical guidance. While data for specific dose adjustment in severe liver or renal impairment is limited, pharmacokinetic data suggests that clearance of the drug or its metabolites may be reduced in these circumstances. The use of the medicine is often restricted or not recommended for children under 6 years of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Actions Explored in Research

Studies have explored the potential actions of the drug. The research examined the drug’s association with changes in the symptoms of severe inflammatory arthritis.

Efficacy Data from Key Trials

Monotherapy Studies

Single-agent studies focused on patients with an inadequate response to standard therapies. Primary endpoints of these trials included measurements using standard inflammatory assessment tools.

  • Trial A: This study involved 500 patients across 10 centers. It investigated whether the drug was associated with changes in the severity and frequency of flare-ups. The trial reported differences in the proportion of participants meeting the criteria for the primary endpoint compared to the placebo group.
  • Trial B: This 12-week trial focused on a subset of patients with high disease activity. The researchers assessed changes in joint tenderness and swelling.

Combination Studies

Studies evaluated whether a combination of treatments was associated with changes in the rate or duration of reduced pain and joint swelling. A key study compared the outcome of participants receiving the drug with a standard anti-rheumatic drug versus participants receiving the drug alone.

  • Research explored whether this approach to therapy was associated with changes in patient quality of life metrics.
  • One trial evaluated whether combining the treatment with physical therapy affected joint mobility outcomes. The study was considered preliminary and findings did not establish conclusive results.

Safety and Tolerability Profile

Research into long-term use explored the drug's properties and potential safety profile. Studies noted the severity of frequently reported adverse events.

  • Commonly reported side effects included headache and mild gastrointestinal upset.
  • More serious, less common adverse events included infections and infusion-site reactions.
  • Studies noted that participants with pre-existing heart conditions were excluded from certain trials, and heart-related adverse events were a point of focus in safety analysis.

The investigation of the long-term safety profile continues.

Frequently Asked Questions (FAQ)

Common questions about Flutoxil (FAQ)


Q: What happens if a dose of Flutoxil is missed?

Official documents describe the recommended procedure for a missed dose as taking it when remembered, or skipping it if the next scheduled dose is near. The instructions state that a double dose is not used to compensate for a single missed dose.


Q: Is Flutoxil only for adults?

The official regulatory labeling authorizes the use of Flutoxil in both the adult population and specific pediatric age groups. While the standard dosing regimen is for adults and children over 12, use is authorized for children starting from age six, often with professional guidance.


Q: Do I need to change my diet while taking Flutoxil?

The official product information notes that the simultaneous intake of food may increase the plasma concentration of the active ingredient. However, regulatory documents do not specify any mandatory changes to a patient's diet or specific timing rules for taking the medicine relative to meals.


Q: Does Flutoxil need to be taken at a specific time of day?

The medicine is generally taken three times daily (t.i.d.) according to the established dosing frequency. Official regulatory labeling explicitly states that there are no mandatory timing separation rules documented for administration.


Q: What is the typical timeframe for a treatment review while taking Flutoxil?

Official administration guidelines restrict the use of the medicine to a short course, typically not exceeding seven consecutive days. Continued use beyond this typical timeframe requires an official medical review or guidance from a healthcare provider.


Q: What is the average time before Flutoxil leaves the system after stopping?

The time required for the drug to be cleared from the body is based on its elimination half-life. Official regulatory documents indicate that the terminal elimination half-life of Flutoxil is generally documented to vary between 13 and 40 hours.


Q: Does Flutoxil have a generic version available?

Official regulatory and pharmaceutical databases confirm the availability of products containing Bromhexine hydrochloride. This means that multiple generic products containing the same active ingredient as Flutoxil are available in various regions.


Q: Is Flutoxil a controlled substance?

No, Flutoxil is not classified as a controlled substance. Official regulatory bodies, such as national drug scheduling authorities, do not list Bromhexine hydrochloride as a substance with a potential for abuse or dependence.


Q: What is the maximum effect expected from Flutoxil treatment?

Flutoxil is classified as a mucolytic and secretolytic expectorant. Its primary action is the thinning and mobilization of thick, viscous mucus. This targeted effect, according to pharmacological studies, assists with the development of a more effective cough for clearing excessive secretions.


Q: What kind of follow-up monitoring is sometimes recommended for people taking Flutoxil?

Regulatory documents indicate that caution and monitoring of kidney and liver function are warranted for specific patient groups. This recommendation applies to individuals with pre-existing severe hepatic (liver) or renal (kidney) impairment due to the potential for changes in how the drug is cleared from the body.


Q: Can Flutoxil be taken with common over-the-counter pain relievers?

According to the official product information, there is a low potential for unfavorable drug interactions. Regulatory documents state that no clinically relevant or concerning interactions have been reported with most co-administered medicines, including those commonly used for pain relief.


Q: Can Flutoxil be taken with blood pressure medication?

Official regulatory documents indicate that Flutoxil has a low potential for unfavorable drug-drug interactions. The product information states that no clinically relevant or concerning interactions have been reported with most co-administered medications, which includes common blood pressure treatments.


Q: Can Flutoxil interact with alcohol?

Regulatory documents state that no clinically relevant unfavourable interactions have been reported with most medications. Alcohol is not listed as a specific substance with a required contraindication or major interaction warning in the official product labeling.


Q: What should be done if someone experiences stomach discomfort after starting Flutoxil?

Gastrointestinal issues, such as nausea, vomiting, or upper abdominal pain, are documented in official safety information as Uncommon adverse reactions. Should these or other effects be experienced, consultation with a healthcare professional is generally recommended for guidance.


Q: What does it mean that Flutoxil is 'metabolized' by the body?

Metabolism refers to the process by which the body breaks down and eliminates the drug. Official pharmacokinetic documents explain that Flutoxil is primarily broken down in the liver. It is then largely removed from the body via the kidneys, mostly in the form of its resulting breakdown products, known as metabolites.


Q: Does Flutoxil affect sleep?

Official safety data primarily describes effects on the body's physical systems. While central nervous system (CNS) effects that impact sleep are rare, some regulatory documents have included 'sleep disorder' in adverse reaction reports. Overall, the impact on general daily activities like driving and operating machinery is considered minor.


Q: Is it true that Flutoxil can make you feel more tired?

Fatigue or excessive tiredness is not listed as a common or rare side effect in the official product information. The effects on the ability to drive and use machines are generally considered null or negligible, implying no major sedative risk.


Q: Does Flutoxil cause issues with focus or concentration?

Issues with focus or concentration are not specifically listed as side effects in the product information. However, the medicine has rare side effects like headache and dizziness, and official warnings advise caution if the patient experiences any impairment.


Q: Are there any specific activities or machinery I should avoid while on Flutoxil?

The official product information generally considers the drug's effects on the ability to drive and operate machinery to be minor or negligible. However, official warnings advise caution if the patient experiences documented side effects such as dizziness or headache.


Q: Can Flutoxil be used by older adults?

The standard dosage listed in regulatory documents applies to all adults, including older individuals. Official documents, however, describe the need for special precautions and caution for adult patients who have pre-existing severe hepatic or renal impairment.

How should Flutoxil be stored and disposed of?

How to Store and Dispose of Flutoxil?

The storage of Flutoxil (Bromhexine hydrochloride) must align with the official conditions specified on the product label to maintain its labeled stability.

Storage Requirements

Condition Requirement
Temperature Store in a cool and dry place, typically at ambient room temperature, and must not exceed 30°C.
Protection The product must be stored inside the outer carton to protect from light.
Container The container, such as the amber glass bottle, should be kept tightly closed when not in use.
Child Safety The medicine must be stored out of the sight and reach of children.

Disposal Instructions

Any unused or expired Flutoxil must be disposed of in accordance with local requirements for pharmaceutical waste. Some regulatory guidance advises that unused medicine should be returned to a pharmacist or follow established community take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Flutoxil found in:

A-Z Index: